Ada boy.
Like sotorasib before it, adagrasib is a novel agent showing promising efficacy for the previously deemed “undruggable” KRAS-mutated non-small cell lung cancer. | Jänne, N Engl J Med 2022
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Like sotorasib before it, adagrasib is a novel agent showing promising efficacy for the previously deemed “undruggable” KRAS-mutated non-small cell lung cancer. | Jänne, N Engl J Med 2022
Comments
Post a Comment